Literature DB >> 9777370

Biochemical characterization of mutant EGF receptors expressed in the hemopoietic cell line BaF/3.

F Walker1, M L Hibbs, H H Zhang, L J Gonez, A W Burgess.   

Abstract

The Epidermal Growth Factor (EGF) receptor appears to require a fully active tyrosine kinase domain to transmit mitogenic signals. However, waved-2 mice carrying a mutation in the alpha-helix C of their EGF-R, which abolishes tyrosine kinase activity, only display a mild phenotype and are fully viable. This suggests that the mutant EGF-R signals through heterodimerization with endogenous, kinase active members of the EGF-R family such as ErbB-2 or ErbB-4. We have examined the biochemistry of EGF-Rs carrying mutations in the alpha-helix C of the human EGF-R (V741G and Y740F), in the ATP binding site (K721R) and at the C-terminus (CT957), by expression in BaF/3 cells which are devoid of EGF-R family members. The in vitro kinase activity of the alpha-helix C EGF-R mutants was severely impaired as a result of reduced phosphotransfer activity without appreciable changes in the affinity for either ATP or peptide substrate. Surprisingly, EGF stimulation of cells carrying the different mutant or wild type EGF-Rs resulted in tyrosine phosphorylation of EGF-R proteins; this phosphorylation was abolished in crude plasma membrane preparations, and appears to be due to activation of a membrane-associated or a cytosolic kinase. Receptor-mediated internalization of EGF was profoundly suppressed in the V741G, K721R and CT957 receptor mutant, and high affinity EGF binding was undetectable in the V741G and K721R receptors. We conclude that specific residues in the C-helix of the EGF-R kinase are essential for full kinase activity; mutations in this region do not affect ATP binding, but impair the receptors' phosphotransfer ability. High affinity binding of EGF is not dependent on tyrosine kinase activity or sequences in the C-terminus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777370     DOI: 10.3109/08977199809017491

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  8 in total

1.  Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.

Authors:  Terrance G Johns; Rodney B Luwor; Carmel Murone; Francesca Walker; Janet Weinstock; Angela A Vitali; Rushika M Perera; Achim A Jungbluth; Elisabeth Stockert; Lloyd J Old; Edouard C Nice; Antony W Burgess; Andrew M Scott
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

2.  Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.

Authors:  Jeonghee Cho; Sandra Pastorino; Qing Zeng; Xiaoyin Xu; William Johnson; Scott Vandenberg; Roel Verhaak; Andrew D Cherniack; Hideo Watanabe; Amit Dutt; Jihyun Kwon; Ying S Chao; Robert C Onofrio; Derek Chiang; Yuki Yuza; Santosh Kesari; Matthew Meyerson
Journal:  Cancer Res       Date:  2011-10-14       Impact factor: 12.701

3.  Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor.

Authors:  Chafen Lu; Li-Zhi Mi; Michael J Grey; Jieqing Zhu; Elizabeth Graef; Shigeyuki Yokoyama; Timothy A Springer
Journal:  Mol Cell Biol       Date:  2010-09-13       Impact factor: 4.272

4.  Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling.

Authors:  Sandra E Nicholson; Donald Metcalf; Naomi S Sprigg; Ruth Columbus; Francesca Walker; Anabel Silva; Dale Cary; Tracy A Willson; Jian-Guo Zhang; Douglas J Hilton; Warren S Alexander; Nicos A Nicola
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-03       Impact factor: 11.205

5.  Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.

Authors:  Thomas P J Garrett; Antony W Burgess; Hui K Gan; Rod B Luwor; Glenn Cartwright; Francesca Walker; Suzanne G Orchard; Andrew H A Clayton; Edouard C Nice; Julie Rothacker; Bruno Catimel; Webster K Cavenee; Lloyd J Old; Elisabeth Stockert; Gerd Ritter; Timothy E Adams; Peter A Hoyne; Dane Wittrup; Ginger Chao; Jennifer R Cochran; Cindy Luo; Mezhen Lou; Trevor Huyton; Yibin Xu; W Douglas Fairlie; Shenggen Yao; Andrew M Scott; Terrance G Johns
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

6.  Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation.

Authors:  F Walker; A Kato; L J Gonez; M L Hibbs; N Pouliot; A Levitzki; A W Burgess
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

7.  Co-conserved features associated with cis regulation of ErbB tyrosine kinases.

Authors:  Amar Mirza; Morad Mustafa; Eric Talevich; Natarajan Kannan
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

8.  Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.

Authors:  Jeffrey C Lee; Igor Vivanco; Rameen Beroukhim; Julie H Y Huang; Whei L Feng; Ralph M DeBiasi; Koji Yoshimoto; Jennifer C King; Phioanh Nghiemphu; Yuki Yuza; Qing Xu; Heidi Greulich; Roman K Thomas; J Guillermo Paez; Timothy C Peck; David J Linhart; Karen A Glatt; Gad Getz; Robert Onofrio; Liuda Ziaugra; Ross L Levine; Stacey Gabriel; Tomohiro Kawaguchi; Keith O'Neill; Haumith Khan; Linda M Liau; Stanley F Nelson; P Nagesh Rao; Paul Mischel; Russell O Pieper; Tim Cloughesy; Daniel J Leahy; William R Sellers; Charles L Sawyers; Matthew Meyerson; Ingo K Mellinghoff
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.